-DOCSTART- -X- O
Eight -X- _ B-Intervention
novel -X- _ I-Intervention
N′- -X- _ I-Intervention
( -X- _ I-Intervention
2-oxoindolin-3-ylidene -X- _ I-Intervention
) -X- _ I-Intervention
-2-propylpentane -X- _ I-Intervention
hydrazide-hydrazone -X- _ I-Intervention
derivatives -X- _ I-Intervention
4a–h -X- _ I-Intervention
were -X- _ O
synthesized -X- _ O
and -X- _ O
fully -X- _ O
characterized -X- _ O
by -X- _ O
IR -X- _ O
, -X- _ O
NMR -X- _ O
( -X- _ O
( -X- _ O
1 -X- _ O
) -X- _ O
H-NMR -X- _ O
and -X- _ O
( -X- _ O
13 -X- _ O
) -X- _ O
C-NMR -X- _ O
) -X- _ O
, -X- _ O
elemental -X- _ O
analysis -X- _ O
, -X- _ O
and -X- _ O
X-ray -X- _ O
crystallography. -X- _ O
The -X- _ O
cyto-toxicity -X- _ O
and -X- _ O
in -X- _ O
vitro -X- _ O
anti-cancer -X- _ O
evaluation -X- _ O
of -X- _ O
the -X- _ O
prepared -X- _ O
compounds -X- _ O
have -X- _ O
been -X- _ O
assessed -X- _ O
against -X- _ O
two -X- _ O
different -X- _ O
human -X- _ B-Patient
tumour -X- _ I-Patient
cell -X- _ I-Patient
lines -X- _ I-Patient
including -X- _ I-Patient
human -X- _ I-Patient
liver -X- _ I-Patient
( -X- _ I-Patient
HepG2 -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
leukaemia -X- _ I-Patient
( -X- _ I-Patient
Jurkat -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
in -X- _ O
normal -X- _ B-Comparison
cell -X- _ I-Comparison
lines -X- _ I-Comparison
derived -X- _ I-Comparison
from -X- _ I-Comparison
human -X- _ I-Comparison
embryonic -X- _ I-Comparison
kidney -X- _ I-Comparison
( -X- _ I-Comparison
HEK293 -X- _ I-Comparison
) -X- _ I-Comparison
using -X- _ O
MTT -X- _ O
assay. -X- _ O
The -X- _ O
compounds -X- _ B-Outcome
3e -X- _ I-Outcome
, -X- _ I-Outcome
3f -X- _ I-Outcome
, -X- _ I-Outcome
4a -X- _ I-Outcome
, -X- _ I-Outcome
4c -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
4e -X- _ I-Outcome
revealed -X- _ I-Outcome
promising -X- _ I-Outcome
anti-cancer -X- _ I-Outcome
activities -X- _ I-Outcome
in -X- _ I-Outcome
tested -X- _ I-Outcome
human -X- _ I-Outcome
tumour -X- _ I-Outcome
cells -X- _ I-Outcome
lines -X- _ I-Outcome
( -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
values -X- _ I-Outcome
between -X- _ I-Outcome
3 -X- _ I-Outcome
and -X- _ I-Outcome
7 -X- _ I-Outcome
μM -X- _ I-Outcome
) -X- _ I-Outcome
as -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
known -X- _ I-Outcome
anti-cancer -X- _ I-Outcome
drug -X- _ I-Outcome
5-Fluorouracil -X- _ I-Outcome
( -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
32–50 -X- _ I-Outcome
μM -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Among -X- _ I-Outcome
the -X- _ I-Outcome
tested -X- _ I-Outcome
compounds -X- _ I-Outcome
, -X- _ I-Outcome
4a -X- _ I-Outcome
showed -X- _ I-Outcome
specificity -X- _ I-Outcome
against -X- _ I-Outcome
leukaemia -X- _ I-Outcome
( -X- _ I-Outcome
Jurkat -X- _ I-Outcome
) -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
IC -X- _ I-Outcome
( -X- _ I-Outcome
50 -X- _ I-Outcome
) -X- _ I-Outcome
value -X- _ I-Outcome
of -X- _ I-Outcome
3.14 -X- _ I-Outcome
μM -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
this -X- _ I-Outcome
compound -X- _ I-Outcome
was -X- _ I-Outcome
inactive -X- _ I-Outcome
in -X- _ I-Outcome
liver -X- _ I-Outcome
cancer -X- _ I-Outcome
and -X- _ I-Outcome
normal -X- _ I-Outcome
cell -X- _ I-Outcome
lines -X- _ I-Outcome
. -X- _ O

